Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04245644Active Not Recruiting

Efficacy of Chemopreventive Agents on Disease-free and Overall Survival in Patients With Pancreatic Ductal Adenocarcinoma: The CAOS Study

Role: lead

NCT04024358Active Not Recruiting

A New Scoring System for Perineural and Vascular Invasion in Pancreatic Cancer

Role: lead

NCT05334290Recruiting

Financial Toxicity and Patient-Reported Outcomes in GEP-NEN During Treatment

Role: lead

NCT04431076Unknown

Patient Reported Outcomes Measures to Predict Pancreatic Surgery Outcomes

Role: lead

All 4 trials loaded